Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Net Change in Cash · Q3 FY2026 · quarter ended Aug 2026

Net change in cash turns positive

Q3 FY2026 net change in cash was $652.37M, compared with -$5.76M a year earlier. Trailing-twelve-month net change in cash was $641.62M.

Context

  • Net change in cash amounted to 163.2% of revenue in FY2025, up 61.7 pp from a year earlier.
  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near $652.37M or moves back toward the trailing-twelve-month quarterly average of $160.4M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterAug 2026
$652.37M+18686.1% QoQ
Last fiscal yearNov 2025
$137.03M+147.5% YoY
LTMAug 2026
$641.62M+3223.9% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11435.7%——
1 year+147.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
137.03M USD
Year-over-year change
+147.5%

Net Change in Cash vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 net change in cash of $641.62M is the largest of the 8 companies compared; the peer median is $12.19M.
  • Its year-over-year change of +3223.9% is the highest of 8, against a peer median of -159.0%.
  • Net change in cash amounts to 91.4% of revenue for NRIX, versus a peer median of 17.0%.
NRIX Competitors Peer median
Net Change in Cash for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M +3223.9%—91.4%
RVMDRevolution Medicines, Inc.LTM Jun 2026$413.94M +226.5%——
KYMRKymera Therapeutics, Inc.LTM Jun 2026$211.34M -178.8%+126.3%201.3%
TNGXTango Therapeutics, Inc.LTM Sep 2026$28.07M +440.8%——
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$23.22M -159.0%-49.3%10.7%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$21.32M -205.5%—7.1%
KURAKura Oncology, Inc.LTM Mar 2026$12.19M -224.8%+24.7%17.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$9.98M +126.0%—28.6%
Peer median (excluding NRIX) $12.19M-159.0%+24.7%17.0%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
Deferred Income Tax00000
Stock-Based Compensation15.8M28.13M33.67M33.93M37.97M
Change in Working Capital9.11M(19.02M)20.12M(18.4M)(31.6M)
Accounts Receivables(6M)6M000
Inventory6.77M0000
Accounts Payables1.59M85K1.61M5.21M(630K)
Other Working Capital6.75M(25.11M)18.51M(23.61M)(30.97M)
Other Non-Cash Items1.83M636K(4.87M)(10.97M)(10.23M)
Operating Cash Flow(84.37M)(159.81M)(81.37M)(172.58M)(249.47M)
Capital Expenditures(5.66M)(12.24M)(8.4M)(9.27M)(14M)
Acquisitions (Net)102.59M(39.44M)000
Purchases of Investments(348.5M)(239.37M)(246.33M)(707.95M)(455.69M)
Sales of Investments245.91M278.81M323.04M459.51M617.54M
Other Investing Activities(102.59M)39.44M000
Investing Cash Flow(108.25M)27.2M68.3M(257.71M)147.85M
Debt Repayment00000
Common Stock Issued150.16M19.4M3.22M478.5M238.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.73M97.79M07.17M0
Financing Cash Flow153.88M117.19M3.22M485.67M238.64M
Effect of Forex Changes0000(67K)
Net Change in Cash(38.73M)(15.42M)(9.85M)55.37M137.03M
Free Cash Flow(90.03M)(172.05M)(89.77M)(181.86M)(263.47M)

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.